Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye ...

Extended-release drug delivery is reshaping the treatment landscape for retinal vascular disease, offering a potential answer to the persistent gap between the efficacy of anti-VEGF therapy in ...

Any patient presenting with new-onset NAION should be asked about PDE-5 inhibitor use—including over-the-counter or online purchases that may not appear on a medication list—and, increasingly, about ...

University of Iowa researchers received federal funding from the NIH to advance an antioxidant -based technology that may ...

InVision Eye Care is using a virtual reality-based patient education tool to show patients with cataracts what their vision ...

Giant cell arteritis, long known by its more familiar name, temporal arteritis, is the most common vasculitis in adults over ...

The phase 3 study is the first pivotal gene therapy trial to evaluate OCU410 in patients with GA secondary to dAMD. The FDA ...

Zhang traced growing interest in home tonometry back to the COVID-19 pandemic, when clinicians needed new ways to track patie ...

Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, ...

Zero Blind Babies uses wide-field retinal imaging and telemedicine to expand ROP screening across Ghana, Ethiopia, Tanzania, ...

Declining estrogen and androgen levels can disrupt lacrimal and meibomian gland function, driving evaporative dry eye during ...

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients ...